Summary of Study ST001908

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001202. The data can be accessed directly via it's Project DOI: 10.21228/M8BD7S This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST001908
Study TitlePost Acute Myocardial Infarction Left Ventricular Remodeling Bio marker Analysis (PAMILA)
Study SummaryPatients with acute myocardial infarction (a condition classified under coronary heart disease, including STEMI and NSTEMI) are at high risk for recurrent ischemic events, but the pathways and factors which contribute to this elevated risk are incompletely understood. This study aims to identify biomarkers associated with acute myocardial infarction through various omics strategies. For the identified biomarkers, we aim to demonstrate prognostic value, and predict/stratify the risks of adverse cardiovascular events (e.g., stroke, heart failure, death).
National University of Singapore
Last NameLim
First NameSi Ying
AddressDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543
Submit Date2021-08-15
Num Groups2
Total Subjects100
Raw Data AvailableYes
Raw Data File Type(s)wiff
Analysis Type DetailLC-MS
Release Date2022-01-21
Release Version1
Si Ying Lim Si Ying Lim application/zip

Select appropriate tab below to view additional metadata details:


Subject ID:SU001986
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Human Inclusion Criteria:a. Clinically diagnosed ST-elevation myocardial infarction (STEMI) • Typical history of ischemic chest pain or angina equivalent symptoms (acute onset dyspnea) • ECG changes of at least 2 contiguous leads of ≥2 mm (0.2 mV) in men or ≥1.5 mm (0.15 mV) in women in leads V2–V3 and/or of ≥1 mm (0.1 mV) in other contiguous chest leads or the limb leads • Presence of Q waves • Typical rise and fall of cardiac enzymes (cTn value exceeding the 99th percentile URL (in ng/L or pg/mL) OR Clinically diagnosed nonST-elevation myocardial infarction (NSTEMI) • ECG changes of ST-segment depression or prominent T-wave inversion and/or • positive biomarkers of necrosis (troponin, CKMB) b. Angiographic findings of >50% occlusion of one or more coronary arteries c. Age>21 years and <85 years, d. Ability to provide written informed consent and comply with study protocol requirements.
Human Exclusion Criteria:a. Patients not able or willing to consent for study b. Severe renal impairment (eGFR<15 ml/min/m2) c. Severe liver impairment d. Anaemia < 8 g/dl (men) and 7 g/dl (women) e. Cardiogenic shock unable to be weaned off inotropes or IABP f. History of significant valvular heart disease (moderate or severe MS, MR, AS, AR, TR) g. History of malignancy diagnosed within the last 12 months h. Patients who cannot be followed up (non-residents)